A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection

NCT02640157 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

506

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C
Hepatitis C Virus
Genotype 3 Hepatitis C Virus

Interventions

DRUG: ABT-493/ABT-530
DRUG: Sofosbuvir
DRUG: Daclatasvir

Sponsor

AbbVie